Chai Discovery tests a new commercial route for AI-designed biologics through Lilly TuneLab
Explore how Chai Discovery and Lilly TuneLab are widening biotech access to AI miniprotein design and what must happen next.
Pharma & Biotech
Pharma & Biotech
Why Veraxa Biotech stock fell 23% after its BiTAC-ADC proof-of-concept data
Veraxa Biotech’s split-component antibody-drug conjugate platform could reduce off-tumour toxicity, but investors received laboratory evidence rather than the clinical roadmap needed to support its newly public valuation.
Medical Devices & Diagnostics
Greenstone Biosciences and Intel chase faster drug discovery as regulators back human-relevant models
Discover how Greenstone Biosciences and Intel plan to scale iPSC drug discovery, and why validation will determine the platform’s impact.
Medical Devices & Diagnostics
Why AngioDynamics stock investors should watch NanoKnife’s move into benign prostate disease
FDA clearance to begin the RELIEF study opens a large benign prostatic hyperplasia opportunity for NanoKnife, but the small trial, general anaesthesia and crowded treatment market leave major commercial questions unanswered.
Medical Devices & Diagnostics
Canada’s healthcare market faces a turning point as Alberta prepares dual-practice surgery launch
Read how Alberta’s September 2026 dual-practice surgery model could reshape capacity, staffing, private payment and patient access.
Pharma & Biotech
AbbVie nears reported $10.9bn Apogee deal as zumilokibart heads toward Phase 3
AbbVie could pay a substantial premium for Apogee Therapeutics and its long-acting eczema antibody, but the reported deal depends on Phase 3 success and differentiation from established immunology drugs.
Pharma & Biotech
Memo Therapeutics advances potravitug as the race for the first BK virus therapy intensifies
Memo Therapeutics’ Phase 2 data show sustained BK polyomavirus reductions and kidney-biopsy improvement, but a missed primary endpoint leaves its pivotal trial carrying the decisive burden.
Pharma & Biotech
CureGene targets clopidogrel variability as evategrel begins a critical United States study
Evategrel could offer rapid and consistent platelet inhibition through oral and intravenous formulations, but early volunteer data cannot establish cardiovascular protection or safety.
Pharma & Biotech
GSK and Spero win Utebzi approval after an earlier FDA rejection and new Phase 3 trial
The first United States-approved oral carbapenem could replace intravenous therapy for selected complicated urinary tract infections, but stewardship, four-times-daily dosing and resistance risks will constrain its use.
Pharma & Biotech
Can uniQure turn the FDA’s AMT-130 reversal into a Huntington’s disease approval?
The Food and Drug Administration will accept uniQure’s three-year AMT-130 data as the primary basis for an accelerated approval filing, but external controls, irreversible brain delivery and confirmatory evidence remain decisive risks.